According to recently released research, patients who suffer from inflammatory bowel disease and major depressive disorder have higher healthcare burdens and discharge rates, as well as increased morbidity.
Major depressive disorder, which is sometimes referred to as clinical depression, affects an individual’s behavior and mood as well as physical functions such as sleep and appetite. This disorder is a common mental health condition in the United States, with data suggesting that more than 7% of adults in the country experience depressive episodes.
On the other hand, inflammatory bowel disease represents various intestinal ailments that bring about prolonged inflammation of an individual’s digestive tract. This disease is disruptive and painful, and may be fatal to some. Crohn’s disease and ulcerative colitis are the most common diseases in this category.
Shiva Shankar Vangimalla, from Medstar Washington Hospital Center’s internal medicine division, explains that new research theorized that bidirectional pathways between inflammatory bowel disease and major depressive disorder (“MDD”), where poor management of ailments could drive depression, could lead to clinical recurrence or onset of inflammatory bowel disease.
Vangimalla notes that in the recent past, various studies conducted in European countries as well as Canada had determined considerably higher frequencies of depression in inflammatory bowel disease patients as well as highlighted the disease’s relation to poor clinical outcomes. However, Vangimalla added, no such literature or data existed on the United States population.
For their study, the researchers used the National Inpatient Sample database to find more than 35,000 patients who had been hospitalized with ulcerative colitis related to major depressive disorder and approximately 70,000 patients who had been hospitalized with Crohn’s disease related to MDD.
The researchers discovered that in comparison with patients who did not suffer from major depressive disorder, MDD’s presence corresponded to a higher length of stay among patients with ulcerative colitis and Crohn’s disease. Additionally, it also corresponded to a higher rate of discharge as well as a severe loss of function.
The investigators also noted that in comparison with patients without major depressive disorder, there were lower inpatient mortality rates for patients with major depressive disorder.
In conclusion, Vangimalla stated, the research demonstrated that there was a considerable burden of major depressive disorder in inflammatory bowel disease patients, particularly in Crohn’s disease than in ulcerative colitis.
Furthermore, he noted, the white race, lower income, females (gender) and older age were the prime epidemiological characteristics of inflammatory bowel disease patients who also suffered from depression. He added that increased discharges and morbidity proposed a higher overall healthcare burden to patients who suffered from depression.
There may be light at the end of the tunnel for these patients given that a number of companies, including Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF), are hard at work developing psychedelic-based treatments for depression and other psychiatric conditions.
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) are available in the company’s newsroom at https://ibn.fm/CYBN
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
